Teva to Present New Analyses of AUSTEDO (deutetrabenazine) Tablets and Assessment of Schizophrenia Clinical Outcomes at Upcoming 2021 American Psychiatric Association Annual Meeting

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced four new posters examining long-term analyses of AUSTEDO (deutetrabenazine) tablets and clinical outcome measures in schizophrenia will be presented at the upcoming 2021 American Psychiatric Association (APA) Annual Meeting taking place May 1-3, 2021.

“These analyses support our ongoing efforts to improve the lives of people with neurological and psychiatric disorders, and we remain committed to driving progress for patients and the physicians who manage their care,” said Denisa Hurtukova, MD, VP, Head of North America Medical Affairs. “We look forward to participating in meaningful scientific exchange at APA around the body of evidence supporting the long-term use of AUSTEDO as a treatment option for tardive dyskinesia, and to foster a deeper understanding of the challenges and unmet needs in the mental health space.”

Teva will highlight long-term efficacy, safety, and tolerability data from the pivotal ARM-TD and AIM-TD clinical trials, as well as a three-year open-label extension study for AUSTEDO in the treatment of tardive dyskinesia (TD). These analyses examined the improvements in quality of life (QoL) and patient-centered outcomes with AUSTEDO by assessing QoL via modified craniocervical dystonia questionnaire (mCDQ-24) scores and patient-centered outcomes via abnormal involuntary movement scale (AIMS) scores through week 106 in a three-year open-label extension study. Exposure-adjusted incidence rates (EAIRs) were used to assess the frequency of adverse events (AEs) through week 145 of the study.

Additionally, Teva will present a comprehensive overview of the clinical outcome measures used in schizophrenia over the past 10 years.

Posters will be available online at the start of the meeting on May 1, 2021 and can be accessed via the APA meeting website at: www.psychiatry.org/annualmeeting.

The full set of Teva-sponsored data to be presented includes:

AUSTEDO

De novo:

• Poster 4849: Long-Term Deutetrabenazine Treatment Is Associated with Sustained Improvements in Quality of Life in Patients with Tardive Dyskinesia
• Poster 4390: Improvements in Patient-Centered Outcome Measures with Long-Term Deutetrabenazine Treatment among patients with Tardive Dyskinesia
• Poster 4807: Long-Term Safety of Deutetrabenazine in Patients with Tardive Dyskinesia: Results from the Completed, 3-year Open-Label Extension Study

Schizophrenia